Search

Your search keyword '"Natalia Paola Schutz"' showing total 4 results
Start Over Author "Natalia Paola Schutz" Language undetermined
4 results on '"Natalia Paola Schutz"'

2. Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup

Author

Humberto Martinez-Cordero, Camila Peña, Natalia Paola Schutz, Virginia Bove, Fiorella Villano, Rocío Osorio, Mauricio Chandia, Cecilia Beltrán, Javier Schulz, Daniela Cardemil, Carolina Contreras, Carmen Gloria Vergara, Javiera Donoso, Marcela Espinoza, Gabriel La Rocca, Hernán López-Vidal, Pilar León, Macarena Roa, Christine Rojas, Pablo Soto, Sandra Aranda, Vivianne Torres, Paola Ochoa, Patricio Duarte, Guillermina Remaggi, Sebastian Yantorno, Ariel Corzo, Soledad Zabaljauregui, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Veronica Verri, Luis Darío Quiroga, Juan Jose Garcia, Vanesa Fernandez, Dorotea Fantl, Jhoanna Ramirez, Alicia Molina, Pilar Papilco, Alex Mite, Ines Reyes, Brenner Sabando Vélez, Francisca M. Ramirez Aspiazu, Claudia Lucia Sossa, Virginia Abello, Henry Idrobo, Domingo Saavedra, Guillermo Quintero, Lina Gaviria, Rigoberto Gomez, Monica Osuna Pérez, Alicia Henao-Uribe, Luz del Carmen Tarín Arzaga, Omar Cantú-Martínez, David Gomez-Almaguer, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Yahveth Cantero-Fortiz, Guillermo J. Ruiz-Arguelles, Eloisa Riva, and Isabella Novoa-Caicedo

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

4. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from

Author

Patricio Jose, Duarte, Natalia Paola, Schutz, Paola, Ochoa, Sebastian, Yantorno, Sergio, Orlando, Sergio, Lopresti, Soledad, Zabaljauregui, Florencia, Aizpurua, Claudia, Shanley, Elvira, Giannini, Gonzalo, Garate, Cecilia, Foncuberta, Jorge, Milone, Dardo, Riveros, and Dorotea, Fantl

Subjects
Latin America, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Recurrence, Local, Multiple Myeloma, Lenalidomide, Dexamethasone, Progression-Free Survival, Retrospective Studies
Abstract

We compared the efficacy of lenalidomide-dexamethasone (Rd) based treatments for relapsed/refractory multiple myeloma patients (pts), in a real-world setting. In addition, we evaluated adverse events (AE), progression-free survival (PFS) and overall survival (OS).In our retrospective, multicentric study, 156 pts with RRMM were included. 74/156 pts (47%) were refractory to bortezomib (V) and 43/156 (27%) pts to lenalidomide (R), with 24/156 (15%) of pts double refractory. Eighty-six pts (55%) received Rd with carfilzomib (KRd), 30 pts (19%) bortezomib (VRd), 30 pts (19%) daratumumab (DRd), and 10 pts (6%) ixazomib (IRd).The overall response (ORR) (≥ partial response) for the entire cohort was 71%, with a very good partial response rate or better (≥VGPR) of 35%. We found no significant differences in CR or ≥VGRP rates between treatments (p:0.229). Regardless of the combination received, those patients who achieved CR had significantly improved PFS (p: 0.007). The most frequent cause of treatment discontinuation was disease progression in 55/156 pts (35%). 8 pts (5%) discontinued treatment due to treatment-related adverse events (AE).This is the first report of Rd combinations for the treatment of RRMM in Latin America. All combinations proved to be effective with an acceptable toxicity.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results